Investors
Press releases
- SynAct Pharma slutför rekryteringen till fas 2a studien BEGIN med AP1189 på nydebuterade patienter med akut reumatoid artrit
- SynAct Pharma completes patient recruitment to the Phase 2a BEGIN study of AP1189 in early severe Rheumatoid Arthritis
- SynAct Pharma: Interim Report January-June 2021 August 27, 2021 (Q2 2021 Report included)
- SynAct Pharma: Halvårsrapport January-June 2021 27 augusti, 2021 (Q2 2021 report included)
